-online.com antibodies

Datasheet for ABIN883793 anti-SMPD1 antibody (AA 201-300) (Alexa Fluor 350)



Overview

Quantity:	100 µL
Target:	SMPD1
Binding Specificity:	AA 201-300
Reactivity:	Human, Mouse, Rat
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This SMPD1 antibody is conjugated to Alexa Fluor 350
Application:	Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Product Details

Immunogen:	KLH conjugated synthetic peptide derived from human Acid sphingomyelinase	
Isotype:	lgG	
Cross-Reactivity:	Human, Mouse, Rat	
Predicted Reactivity:	Dog,Cow,Pig,Rabbit	
Purification:	Purified by Protein A.	
Target Details		
Target:	SMPD1	
Alternative Name:	Acid sphingomyelinase (SMPD1 Products)	

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 1/3 | Product datasheet for ABIN883793 | 03/06/2024 | Copyright antibodies-online. All rights reserved.

phosphodiesterase 1 acid lysosomal, Sphingornyelin phosphodiesterase. Background: Converts sphingornyelin to ceramide. Also has phospholipase C activities toward 1.2 diacylglycerolphosphocholine and 1.2-diacylglycerolphosphoglycerol. Isoform 3 have lost catalytic activity. Involvement in disease: Defects in SMPD1 are the cause o Niemann-Pick disease type A (NPDA), also known as Niemann-Pick disease classical infantile form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze sphingornyelin to ceramide. It results in the accumulation of sphingornyelin and ther metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder, characterized by onset within the first year of file, mental retardation, digestive disorders, failure to thrive, major hepatosphenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Cene ID: 6609 UniProt: P17405 Application Notes: IF(IHC-P) 1:50-200 IF(ICC-P) 1:50-200 IF(ICC-P) 1:50-200 IF(ICC-P) 1:50-200 IF(ICC-P) 1:50-200 IF(ICC-P) 1:50-200 IF(ICC-P) 1:50-200 IF(ICC-P) 1:50-200 IF(ICC-P) 1:50-200 IF(ICC-P	Background:	Synonyms: Acid sphingomyelinase, ASM, ASM_HUMAN, aSMase, NPD, Smpd1, Sphingomyelin
Background: Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1.2-diacylglycerolphosphocholine and 1.2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic activity. Involvement in disease: Defects in SMPD1 are the cause o Niemann-Pick disease type A (NPDA), also known as Niemann-Pick disease classical infantile form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorders. failure characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Cene ID: 6609 UniProt: P17405 Application Notes: IF(IHC-P) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 For Research Use only For Research Use only Handling Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.		
1,2-diacy[g]ycero]phosphocholine and 1,2-diacy[g]ycero]phosphoglycerol. Isoform 2 and isoform 3 have lost catalytic activity.Involvement in disease: Defects in SMPD1 are the cause on Niemann-Pick disease type A (NPDA), also known as Niemann-Pick disease classical infantile form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body. leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder: characterized by onset within the first year of life, mental retardator, digestive disorders, failure to thriter, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompases a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Handling Iuquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.		
isoform 3 have lost atalytic activity involvement in disease: Defects in SMPD1 are the cause on Niemann-Pick disease type A (NPDA), also known as Niemann-Pick disease classical infantile form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder: characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediati types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(HC-P) 1:50-200 IF(IC-P) 1:50-200 IF(IC-P) 1:50-200 IF(IC-C) 1:50-200 IF(IC-C) 1:50-200 IF(IC-C) 1:50-200 IF(IC-C) 1:50-200 Handling For Research Use only Handling Iugud Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.		
form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, offen around the age of four. Olinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-P) 1:50-200 IF(IHC-F) I:50-200 IF(IHC-F) I:50		
sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuleendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorders, characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediati types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC) 1:50-200 IF(IHC)		Niemann-Pick disease type A (NPDA) , also known as Niemann-Pick disease classical infantile
metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(HC-P) 1:50-200 IF(HC-F) 1:50-200 IF(HC-F) 1:50-200 IF(HC		form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze
leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IC) 1:50-200 IF(IC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Buffer: Cugud Concentration: 1 µg/µL		sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other
characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-P) 1:50-200 IF(IHC-P) 1:50-200 IF(IC) 1:50-200 IF(IHC-P) 1:50-200 IF(IC) 1:50-200 IF(IC) 1:50-200 IF(IC) 1:50-200 IF(IEC) 1:50-200 IF(IC) 200 IF(IEC) 1:50-200 IF(IEC) 1:50-200 IF(IEC) 1:50-200		metabolically related lipids in reticuloendothelial and other cell types throughout the body,
to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(IHC-F) 1:50-200 IF(IRC-F) 1:50-200 IF(IRC-F) 1:50-200 IF(IRC-F) 1:50-200 IF(IRC-F) 1:50-200 IF(IRC-F) 1:50-200 IF(IRC-F) II IF(IRC-F) 1:50-200 IF(IRC-F) II IF(IRC-F) 1:50-200 IF(IRC-F) II IF(IRC-F) 1:50-200 IF(IRC-F) II IF(IRC-F) II IF(IRC-F) II IF(IRC-F) II IF(IRC-F) II <		leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder
neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Buffer: Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		characterized by onset within the first year of life, mental retardation, digestive disorders, failure
four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediati types encompass a cluster of variants combining clinical features of both types A and B.Gene ID:6609UniProt:P17405Application Details[F(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200Restrictions:For Research Use onlyHandling[uiqiidConcentration:1 µg/µLBuffer:Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and S0 % Glycerol.Preservative:ProClin		to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe
neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details F(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Eoncentration: Iuquid 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		neurological disorders and pulmonary infections lead to an early death, often around the age of
types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(CC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Iuid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		four. Clinical features are variable. A phenotypic continuum exists between type A (basic
Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Iuiquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate
UniProt: P17405 Application Details Application Notes: IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Format: Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		types encompass a cluster of variants combining clinical features of both types A and B.
Application Details Application Notes: IF(IHC-P) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Iuiuid Format: Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Gene ID:	6609
Application Notes: IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Iuiuid Format: Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	UniProt:	P17405
IF IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Format: Liquid Concentration: 1 μg/μL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Application Details	
IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Format: Liquid Concentration: 1 μg/μL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Application Notes:	IF(IHC-P) 1:50-200
Restrictions: For Research Use only Handling Liquid Format: Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		IF(IHC-F) 1:50-200
Handling Format: Liquid Concentration: 1 μg/μL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		IF(ICC) 1:50-200
Format: Liquid Concentration: 1 μg/μL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Restrictions:	For Research Use only
Concentration: 1 μg/μL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Handling	
Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Format:	Liquid
50 % Glycerol. Preservative: ProClin	Concentration:	1 μg/μL
	Buffer:	
Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be	Preservative:	ProClin
	Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 2/3 | Product datasheet for ABIN883793 | 03/06/2024 | Copyright antibodies-online. All rights reserved.

lond	lina
land	

	handled by trained staff only.
Storage:	-20 °C
Storage Comment:	Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Expiry Date:	12 months